

**Table S1: Chemotherapy regimen for high-risk group neuroblastoma ( CCGG-NB 2015 )**

Course	Scheme
1	CTX*+TOPO
2	CTX*+TOPO
	Response evaluation
3	CDDP+VP-16
4	CTX+DOXO+VCR+MESNA
	Response evaluation
	Autologous peripheral blood stem cell collection
	Operation
5	CDDP+VP-16
6	CTX+DOXO+VCR+MESNA
	Response evaluation
7	CTX*+TOPO
8	CDDP+VP-16
	Response evaluation
undergo HSCT	Not undergo HSCT
ABMT1	CTX+DOXO+VCR+MESNA
Radiotherapy	CTX*+TOPO
ABMT2	CDDP+VP-16
	CTX+DOXO+VCR+MESNA
	Radiotherapy
	Response evaluation
13-cis-RA 160mg/m <sup>2</sup> , 14day/month, total of 6 months	

Cyclophosphamide(CTX)\*: 400 mg/m<sup>2</sup>. d1-d5( <12 kg: 13.3 mg/kg)

Topotecan(TOPO): 1.2 mg/m<sup>2</sup>. d1-5.(Replaced by Irinotecan, 120mg/m<sup>2</sup>. d1-3 )

Cisplatin(CDDP): 50 mg/m<sup>2</sup>. d1-4 (< 12kg: 1.66 mg/kg)

Etoposide(VP-16): 200 mg/m<sup>2</sup>. d1-3 (<12 kg: 6.67 mg/kg)

Cyclophosphamide(CTX): 1800 mg/m<sup>2</sup>.d1-2 (< 12 kg: 60mg/kg)

Mesna: 420 mg/m<sup>2</sup>. d1-2 q4hx3

Epirubicin(DOXO): 25 mg/m<sup>2</sup>. d1-3 (< 12 kg: 0.83mg/kg)

Vincristine(VCR): < 12 mon: 0.017mg/kg d1-3

> 12 mon and> 12 kg: 0.67 mg/m<sup>2</sup> d1-3

>12 mon and< 12 kg: 0.022 mg/kg d1-3